Septerna, Inc. (SEPN) analyst actions
Rating and price-target actions on SEPN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SEPN overview →
3 measured SEPN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism | Press release | +1.74% | +1.48% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out | Press release | +0.46% | +8.07% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out | Press release | +1.39% | +2.68% |
Keep exploring
More SEPN: earnings → · SEC filings → · SEPN overview →